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Available online 11 January 2014Susac syndrome (SS) is an autoimmune disease characterized by the clinical triad of encephalopathy, branch retinal
artery occlusions and neuro-sensorial hearing loss; it is due to a microangiopathy affecting the precapillary arteri-
oles of the brain, retina and inner ear. SS is characterized by typical radiological features on magnetic resonance
imaging (MRI) which, together with clinical symptoms, may permit a diagnosis. Branch retinal artery occlusions
(BRAOs) are best evaluated using ﬂuorescein angiography (FA) which may show the typical multifocal ﬂuores-
cence. SS is an autoimmune endotheliopathy that requires treatment with immunosuppressive agents: steroids,
azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide and intravenous immunoglobulin, usually
in combination. Plasma exchange is also useful. In addition, antiplatelet agents may be a useful adjunct. Correct
immunosuppressive therapy results in signiﬁcant clinical and radiological improvement. An early diagnosis and
treatment are important to delay the disease progression and prevent permanent disability.
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Susac syndrome (SS) is an infrequent neurological disorder that
is characterized by the clinical triad of encephalopathy, branch retinal
artery occlusions (BRAOs) and hearing loss. It is an autoimmune-unes, Hospital Clínic, Villarroel
5774; fax: +34 93 227 1707.
ghts reserved.mediated microangiopathy (precapillary arterioles) that affects the
microvasculature of the brain, retina, and inner ear [1]. It affects
middle-aged women and is probably underdiagnosed due to the irreg-
ular clinical presentation: the three components of the triad do not
usually present at the same time and there is often multisystemic
involvement that imitates other disorders, delaying the time to diagno-
sis. Encephalopathy is frequently the ﬁrst manifestation and is usually
associated with headaches, multifocal neurologic manifestations, and
psychiatric features [2].
Table 1
Cerebral manifestations.
• Headache
• Psychiatric disturbances
• Cognitive changes
• Seizures
• Memory loss
• Long tract signs
• Cranial nerve affectation
• Dysarthria
• Dementia
Table 2
Distinctive FA features in SS.
• Branch retinal artery occlusions (BRAO) 100%.
• Arteriolar wall hyperﬂuorescence (Gass plaques).
• Presence of “leakage”.
• Absence of intraocular inﬂammation associated with occlusion of retinal arterioles
and normal choroidal circulation.
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best evaluated using ﬂuorescein angiography (FA), which may show
the typical multifocal ﬂuorescence. Gass plaques are frequently present
and reﬂect endothelial damage [3].
Magnetic resonance imaging (MRI) shows characteristic white mat-
ter disturbances, lesions of the central ﬁbers of the corpus callosum and
intracranial leptomeningeal enhancement [4]. In addition, brain biopsy
shows microinfarction, while more recent pathological studies have
shown endothelial changes typical of antiendothelial cell injury.
2. History
The syndrome was ﬁrst described by John O. Susac in 1979 in two
young women with the classic clinical triad, but was designated as
Susac syndrome by Hoyt in 1986 [3]. Other acronyms and names in-
clude SICRET (small infarcts of cochlear, retinal, and encephalic tissue);
RED-M (retinopathy, encephalopathy, deafness-associated microangi-
opathy) and retinocochleocerebral vasculopathy [5].
3. Epidemiology
The female/male ratio is 3:1. SS principally affects women aged
20–40 years but cases have been reported in patients aged 7–70 years
[6]. The true incidence is unknown: there are 304 reported cases world-
wide [7].
4. Etiopathogenesis
SS is considered an autoimmune microangiopathy; the microvessel
occlusions are presumed to be mediated by an autoimmune response
(anti-endothelial cell antibody) to an as yet unknown antigen causing
microvascular injury: small infarcts in the brain, cochlea and retina;
these anti-endothelial cell antibodies may be detected in some patients.
Anti-endothelial cell antibodies are not speciﬁc to SS and have been
identiﬁed in other autoimmune diseases [8–10]. Therefore, SS has auto-
immune characteristics. On the other hand, SS has also been suggested
to represent an autoimmune endotheliopathy/coagulopathy similar to
catastrophic antiphospholipid syndrome [10]. It is hypothesized that
antiphospholipid and/or anti-endothelial cell antibodies may play a
role in either mediating or reﬂecting endothelial cell injury in SS [6–10].
Some reports have associated SS and pregnancy. They suggest that
patients with a recent diagnosis of SS developed BRAO during pregnancy
and may present a relapse in the postpartum period or in subsequent
pregnancies. While this may be due to chance or to other autoimmune
conditions in the perinatal period, it is conceivable that ﬂuctuations in
circulating hormones may be relevant to the underlying mechanism of
SS, perhaps by inducing a hypercoagulable state [10–14].
Other entities such as viral infections, idiopathic vasospasm and
hypercoagulable phenomena have been suggested as causes of SS but
evidence is lacking.
5. Clinical manifestations
5.1. Encephalopathy
Headache is reported as themost common prodromal symptom and
may appear severalmonths before the development of encephalopathy,
accompanied by psychiatric disturbances (behavioral changes, para-
noia), cognitive changes, memory loss, and confusion and may rapidly
progress to dementia. Neurological signs and symptoms due tomultifo-
cal vasculitis include variable degrees of dysarthria, dysmetria, vertigo,
long tract signs, cranial nerve involvement and seizures [3,15]. In
addition, cauda equina syndrome with MRI ﬁndings showing diffuse
enhancement of the nerve roots of the cauda equina has recently been
described in a middle-aged male with SS [8]. In a pregnant woman,multifocal motor neuropathy was the ﬁrst manifestation of SS, with a
relapse in a subsequent pregnancy [14] (Table 1).5.2. Ocular involvement
BRAOs are always present. They tend to be bilateral, multiple, widely
disseminated in the retina and temporally separated for severalmonths.
They cause scotoma or photopsias.
Ophthalmic examination usually shows an area of retinal infarction.
Other ﬁndings include cottonwool spots, retinal artery occlusions, areas
of arterio-arterial retinal collaterals and, rarely, neovascularization of
the optic disk, and macular edema. Extensive intra-retinal blot hemor-
rhages and venous–venous collaterals have also been reported [6].
Ophthalmic examinations and FA studies are useful to establish the
ocular features that occur in patients with SS (Table 2). Dilated fundus
examination will reveal BRAOs, which are best evaluated with FA,
which may show the typical multifocal ﬂuorescence [3] and arteriolar
wall hyperﬂuorescence (Gass plaques), which are yellow-white deposits
often proximal to sites of occlusion that suggest endothelial dysfunction
rather than an embolic disorder [16–19].
Thewhitematerial in the arterial lumenmay represent aggregations
of immune complexes or debris from the damaged endothelium. Gass
plaques may appear as a “string of pearls” and should not be mistaken
for emboli or cholesterol deposits. The retinal disease of SS does not in-
volve emboli. Furthermore, emboli are located at bifurcations of vessels,
whereas Gass plaques are found away from sites of bifurcation.
Another ﬁnding is “leakage” due to the combination of loss of tight-
junctions and of integrity of the blood vessel wall. Whenever this “leak-
age” is seen, it is an indication of active disease. This “leakage” can be
seen on FA even when the patient is asymptomatic and has a normal
retinal appearance on the ophthalmoscope or other routine retinal
photos. Therefore, “leakage” on FA is one of the most sensitive ways to
detect evidence of active disease even in asymptomatic patients, and
can be considered as a bio-marker of disease activity.
Optical coherence tomography (OCT) can be used as a diagnostic
tool to analyze the morphological integrity of retinal structures which
permit the identiﬁcation of the characteristic patterns of retinal pathol-
ogy and is useful for differentiating SS from multiple sclerosis [20].
Some patients with extensive arteriolar involvement develop optic
atrophy and signiﬁcant constriction of the visual ﬁeld. The absence of
intraocular inﬂammation, associated with occlusion of retinal arterioles
and normal choroidal circulation, is one of the ophthalmologic charac-
teristics highly suggestive of SS [6].
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Cochlear end-arteriole occlusion, especially at the apex, occurs in the
inner ear in SS. Hearing loss may be unilateral or bilateral, and is usually
asymmetrical and involves mainly the low and mid-frequencies.
Pure tone audiometry usually reveals bilateral neuro-sensorial hear-
ing loss which is asymmetric and is thought to be a sequela of micro-
infarction in the apical cochlea. Low-to-moderate range frequencies
are preferentially affected and poor speech discrimination is common.
Vestibular symptoms may be due to peripheral or central vestibular
involvement. Vertigo and tinnitus often accompany the hearing loss.
Videonystagmography may show a deﬁcit of caloric response of the
affected ear [6,21].
6. Diagnosis
The diagnosis is based primarily on the clinical presentation, the
documentation of BRAO, the presence of typical features on FA, and
the characteristic ﬁndings on cerebral MRI that help distinguish SS
from other inﬂammatory entities, such as multiple sclerosis and acute
disseminated encephalomyelitis.
6.1. Imaging ﬁndings
MRI is the neuroimaging study of choice (Table 3). The characteristic
MRI ﬁndings include central corpus callosum involvement and brain
infarctions. The cerebellum, cerebellar peduncles, brain stem and thala-
mus are occasionally involved. The deep gray matter is involved in
around 70% of cases and the leptomeninges in around 33% [2,22].
T2-weighted images typically show multifocal small hyperintense
foci that involve mainly the central part of the corpus callosum but
spare the periphery. Findings include multiple small hyperintense foci
on T2-weighted images and contrast enhancement in the white and
gray matter of both the supratentorial and infratentorial structures,
the corpus callosum and, occasionally, the leptomeninges.
Fluid-attenuated inversion recovery (FLAIR) may show lesions in
the corpus callosum centrally located in the periventricular white matter
and subcortical white matter. The T2-FLAIR sequence often shows
hyperintensity lesions in the corpus callosum, cortex, centrum semiovale,
and periventricular region of the cerebellum and brainstem. T1-weighted
MRI shows hypointense areas during the subacute or late phase of SS
[23–25].
During the encephalopathy, the corpus callosum is always affected
and MRI shows a characteristic pattern of small-to-large round white
matter lesions (“snowballs”) (sagittal T2 FLAIR) and linear defects
(“spokes”) found in the central ﬁbers of the corpus callosum; as the
acute changes resolve, central callosal “holes” (sagittal T1) develop.
Axial T1 with gadolinium shows leptomeningeal enhancement in the
cerebellum. These characteristics are considered very typical [2,6].
SS can be differentiated from demyelinating disease; in SS, the
callosal white matter lesions typically involve the central ﬁbers withTable 3
Distinctive imaging features in SS.
MRI
• Multiple small hyperintense foci “snowball images” and contrast enhancement.
• White matter. Corpus callosum periventricular area (100%).
• Gray matter (up to 70%).
• Leptomeninges (30%).
• Linear defects “spokes” in the central ﬁbers of the corpus callosum.
• Subacute phase: central callosal “holes”.
• DWI shows hyperintense lesions, “string of pearls”, in the internal capsule and
multiple lesions in the genu and splenium.
DTI
• Microstructural degeneration in the genu of the corpus callosum.relative sparing of theperiphery, and deep graymatter lesions occurring
in SS are never seen in multiple sclerosis.
The lesions are frequently enhanced andmay be evident on diffusion
weighted imaging (DWI), which shows hyperintense lesions, a “string
of pearls” in the internal capsule and multiple lesions in the genu and
splenium [17]. DWI and the apparent diffusion coefﬁcient have been
shown to be sensitive to the histologic and physiologic changes associ-
ated with brain infarction. During the acute phase, infarcted cerebral
tissue is hyperintense on diffusion-weighted MRI and has a reduced
apparent diffusion coefﬁcient [26,27].
Diffusion tensor imaging (DTI) is a noninvasive technique for the
detection of macro- and microstructural impairment of brain tissue
ﬁber (axons of white matter) integrity on the basis of normal values
for fractional anisotropy. DTI is much more sensitive than conventional
MRI in demonstrating white matter abnormalities in SS. DTI has shown
evidence ofwidespread axonal damage not visible on conventionalMRI.
Speciﬁcally, microstructural degeneration in the genu of the corpus
callosum on DTI appears to be characteristic of SS [28].
Other imaging tests have been used but have not provided relevant
ﬁndings. Computed tomography normally yields some extension and
brain single photon emission computed tomography (SPECT) shows
multifocal involvement (hypoperfusion areas) that conﬁrms themicro-
angiopathy [6]. Cerebral angiography is usually normal because the
affected arterioles are too small.
6.2. Other studies
Brain biopsies show perivascular inﬂammation of the small vessels
and microinfarcts of the brain. Necrosis is not found in the vessel walls,
showing that this is a vasculopathy (microangiopathy) rather than a vas-
culitis. More recent pathological studies have shown endothelial changes
that are typical for anti-endothelial cell antibodies. In support of an
antibody-mediated etiology for SS, more than 50% of capillaries in brain
biopsy specimens stain strongly for the complement protein C4d2 [3,6].
Muscle biopsy may show periarteriolar inﬁltrate and swollen endo-
thelial cells whose volume may increase to the point of occlusion of
small arterioles. Microvascular endotheliopathy is also present in the
brain, retina, and inner ear [29].
6.3. Laboratory ﬁndings
Cerebrospinal ﬂuid examination shows lymphocytic pleocytosis and
elevated protein levels, usually during the encephalopathic phase and,
occasionally, elevatedmyelin basic protein [30]. There are no oligoclonal
bands or elevated IgG index; their presence may be misinterpreted as
being due to multiple sclerosis.
Laboratory tests may reveal elevated acute phase reactants. Mild ele-
vations of antinuclear and antiphospholipid antibodies may be found.
There may be elevated factor VIII and von Willebrand factor antigen
levels, possibly due to endothelial perturbation, as their close association
with the endothelium would be consistent with endotheliopathy [3].
7. Treatment
The lack of randomized controlled therapeutic trials means that it
is not possible to recommend standardized guidelines. Possible treat-
ments are based on the results of clinical experience supported by indi-
vidual reports and case series. There is agreement that high dose
corticosteroids should be the ﬁrst line therapy and early, aggressive,
sustained immunosuppressive treatment may markedly improve out-
comes. However, it remains unclear as to how much immunosuppres-
sive medication is required and for how long [30].
The most commonly used immunosuppressive agents include in-
travenous immunoglobulin (IVIg), plasma exchange, azathioprine,
mycophenolate mofetil (MMF), methotrexate, cyclosporin A and cy-
clophosphamide. Ideally, they can improve the disability due to
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improvement or stabilization in some patients treated with IVIg or
plasma exchange [12].
Although patientsmay respond dramatically to corticosteroid thera-
py, SS sometimes needs more than just corticosteroid therapy. Many
patients have responded well to immunosuppressive therapy, but
have relapsed and have responded again to the reinstitution or escala-
tion of immunosuppression to prevent disabilities [30].
Anticoagulation therapy can be helpful, especially in those cases
with antiphospholipid antibodies [10].
Intratympanic injection of dexamethasone in the acute phase of
hearing loss and tinnitus may provide transient beneﬁt with respect to
deafness and may help justify more aggressive immunotherapy on the
grounds of potential for reversibility. In patients with profound neuro-
sensorial hearing loss, cochlear implants may be the best option [31].8. Prognosis
The clinical course in SS may be monocyclic, polycyclic or chronic
continuous. SS has a good prognosis when treatment is early. Recovery
may be almost complete despite signiﬁcant encephalopathy at presen-
tation in patients in whom early diagnosis has led to early administra-
tion of immunosuppressive therapy. However, the diagnosis is usually
delayed, resulting in sequelae. Approximately 50% of patients have
ongoing cognitive impairment.References
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